Article (Scientific journals)
Toward Omics-Based, Systems Biomedicine, and Path and Drug Discovery Methodologies for Depression-Inflammation Research
Maes; Nowak, Gabriel; Caso, Javier et al.
2016In Molecular Neurobiology, 53 (5), p. 2927-2935
Peer reviewed
 

Files


Full Text
MolNeurobiol_depression_inflammation_postprint.pdf
Author postprint (221.31 kB)
Download

All documents in ORBilu are protected by a user license.

Send to



Details



Abstract :
[en] Meta-analyses confirm that depression is accompanied by signs of inflammation including increased levels of acute phase proteins, e.g., C-reactive protein, and pro-inflammatory cytokines, e.g., interleukin-6. Supporting the translational significance of this, a meta-analysis showed that anti-inflammatory drugs may have antidepressant effects. Here, we argue that inflammation and depression research needs to get onto a new track. Firstly, the choice of inflammatory biomarkers in depression research was often too selective and did not consider the broader pathways. Secondly, although mild inflammatory responses are present in depression, other immune-related pathways cannot be disregarded as new drug targets, e.g., activation of cell-mediated immunity, oxidative and nitrosative stress (O&NS) pathways, autoimmune responses, bacterial translocation, and activation of the toll-like receptor and neuroprogressive pathways. Thirdly, anti-inflammatory treatments are sometimes used without full understanding of their effects on the broader pathways underpinning depression. Since many of the activated immune-inflammatory pathways in depression actually confer protection against an overzealous inflammatory response, targeting these pathways may result in unpredictable and unwanted results. Furthermore, this paper discusses the required improvements in research strategy, i.e., path and drug discovery processes, omics-based techniques, and systems biomedicine methodologies. Firstly, novel methods should be employed to examine the intracellular networks that control and modulate the immune, O&NS and neuroprogressive pathways using omics-based assays, including genomics, transcriptomics, proteomics, metabolomics, epigenomics, immunoproteomics and metagenomics. Secondly, systems biomedicine analyses are essential to unravel the complex interactions between these cellular networks, pathways, and the multifactorial trigger factors and to delineate new drug targets in the cellular networks or pathways. Drug discovery processes should delineate new drugs targeting the intracellular networks and immune-related pathways.
Disciplines :
Neurology
Biotechnology
Author, co-author :
Maes
Nowak, Gabriel
Caso, Javier
Leza, Juan Carlos
Song, Cai
Kubera, Marta
Klein, Hans
Galecki, Pjotr
Noto, Cristiano
Glaab, Enrico  ;  University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB)
Balling, Rudi ;  University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB)
Berk, Michael
External co-authors :
yes
Language :
English
Title :
Toward Omics-Based, Systems Biomedicine, and Path and Drug Discovery Methodologies for Depression-Inflammation Research
Publication date :
2016
Journal title :
Molecular Neurobiology
Volume :
53
Issue :
5
Pages :
2927-2935
Peer reviewed :
Peer reviewed
Available on ORBilu :
since 06 May 2015

Statistics


Number of views
281 (46 by Unilu)
Number of downloads
708 (12 by Unilu)

Scopus citations®
 
33
Scopus citations®
without self-citations
25
OpenCitations
 
29
WoS citations
 
36

Bibliography


Similar publications



Contact ORBilu